Contrafect Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Contrafect Contact Number

Contact Us :: ContraFect Corporation (CFRX)

7 hours ago Contrafect.com Show details

(914) 207-2300Contact Us. 28 Wells Ave Yonkers, NY 10701 (914) 207-2300. Contact Form. Name. View available positions at Contrafect and grow your career! Learn More » About Contrafect Corporation. We are focused on developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases. Learn More »

1. 28 Wells Ave, Yonkers, NY 10701 · (914) 207-2300DIRECTIONSWEBSITE

Category: Contact SupportShow more

Profile :: ContraFect Corporation (CFRX)

3 hours ago Ir.contrafect.com Show details

914-207-2300Address: 28 Wells Avenue 3rd Floor Yonkers, NY 10701 US. Telephone: 914-207-2300. Email: [email protected]contrafect.com

Category: Contact NumberShow more

ContraFect Corporation (CFRX)

7 hours ago Contrafect.com Show details

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.

Category: Contact NumberShow more

Contrafect Corporation Company Profile Yonkers, NY

6 hours ago Dnb.com Show details

(914) 207-2300Find company research, competitor information, contact details & financial data for Contrafect Corporation of Yonkers, NY. Get the latest business insights from Dun & Bradstreet.

Employees: 31
Phone: (914) 207-2300
Location: 28 Wells Ave Ste 3, Yonkers, 10701-7045, NY

Category: Contact NumberShow more

ContraFect Crunchbase Company Profile & Funding

Just Now Crunchbase.com Show details

Phone Number 9142072300 ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses.

Founded: 2008
Founder: Robert Nowinski

Category: Contact NumberShow more

Press Releases :: ContraFect Corporation (CFRX)

7 hours ago Ir.contrafect.com Show details

914-207-2300ContraFect Corporation Tel: 914-207-2300 Email: [email protected]contrafect.com. Carlo Tanzi Kendall Investor Relations Tel: 617-914-0008 Email: [email protected] Source: ContraFect Corporation Released July 20, 2020

Category: Contact NumberShow more

ContraFect Corp LinkedIn

8 hours ago Linkedin.com Show details

ContraFect Corp 2,140 followers on LinkedIn. focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections We are a biotechnology

Category: Contact NumberShow more

ContraFect Company Profile Office Locations, Competitors

9 hours ago Craft.co Show details

ContraFect has 24 employees at their 1 location. See insights on ContraFect including office locations, competitors, revenue, financials, …

Category: Contact NumberShow more

CONTRAFECT Corp (Form: S1, Received: 04/18/2014 15:09:26)

5 hours ago Content.edgar-online.com Show details

125-14-1490ContraFect Corporation 28 Wells Avenue, Third Floor Yonkers, New York 10701 (914) 207-2300 (Name, address, including zip code, and telephone number, including area code, of agent for service) With copies to:

Category: Contact NumberShow more

CFRX ContraFect Corporation • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today …

Category: Contact NumberShow more

Xbox Support

1 hours ago Support.xbox.com Show details

You need to enable JavaScript to run this app.

Category: Support NumberShow more

Contact Us CONTRAVE®

2 hours ago Contrave.com Show details

800-905-5576Contact Us. For any questions regarding patient programs, including the CONTRAVE Savings Coupon Card, please call 1-800-905-5576 between the hours of 8 a.m. and 8 p.m. EST, Monday through Friday. Keep in mind that our customer service representatives are not medically trained and will encourage you to work closely with your doctor while taking

Category: Contact SupportShow more

CONTRAFECT CORPORATION : CFRX Stock Price US2123263004

5 hours ago Marketscreener.com Show details

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings.

Category: Contact NumberShow more

Contrafect Corp (CFRX) 10K Annual Reports & 10Q SEC

6 hours ago Last10k.com Show details

The following information was filed by Contrafect Corp (CFRX) on Tuesday, March 30, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the

Category: Contact NumberShow more

ContraFect Corporation to Present at the 2021 Cantor Global

1 hours ago Globenewswire.com Show details

YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents

Category: Contact NumberShow more

What Do Analysts Say About ContraFect Corporation (CFRX

1 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 39.33 million. CFRX does have institutional investors; and they hold 64.00% of the stock. ContraFect Corporation – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

ContraFect Reports Fourth Quarter and Full Year 2020

4 hours ago Finance.yahoo.com Show details

ContraFect also successfully raised $57.5 million in a public equity offering, providing additional resources to support the Company’s promising pipeline programs,” said Roger J. Pomerantz, M

Category: Contact NumberShow more

ContraFect How Have the Numbers Shaped Up for Stock market

5 hours ago Stockmarketdaily.co Show details

Analyst Opinion on ContraFect (NASDAQ:CFRX) 4 Wall Street analysts have issued ratings and price targets for ContraFect in the last 12 months. Their average twelve-month price target is $16.63, predicting that the stock has a possible upside of 271.09%.

Category: Contact NumberShow more

CONTRAFECT Corp (Form: 8K, Received: 05/10/2016 16:15:23)

3 hours ago Content.edgar-online.com Show details

125-16-5855ContraFect Corporation (Exact name of registrant as specified in its charter) Delaware 001-36577 Registrant’s telephone number, including area code N/A (Former Name or Former Address, if Changed Since Last Report) The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such

Category: Contact NumberShow more

CFRX Stock Price ContraFect Corp. Stock Quote (U.S

8 hours ago Marketwatch.com Show details

Number of Ratings 4 Full Ratings . Recent News. ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including

Category: Contact NumberShow more

An indepth look at the ContraFect Corporation (CFRX

9 hours ago Marketingsentinel.com Show details

ContraFect Corporation (NASDAQ:CFRX)’s Major holders. Insiders own 8.76% of the company shares, while shares held by institutions stand at 62.53% with a share float percentage of 68.54%. Investors are also buoyed by the number of investors in a company, with ContraFect Corporation having a total of 84 institutions that hold shares in the company.

Category: Contact NumberShow more

ContraFect Funding, Financials, Valuation & Investors

9 hours ago Crunchbase.com Show details

ContraFect has raised a total of $134.4M in funding over 8 rounds. Their latest funding was raised on Mar 18, 2021 from a Post-IPO Equity round. ContraFect is registered under the ticker NASDAQ:CFRXU . ContraFect is funded by 3 investors. CARB-X and CARB-X are the most recent investors.

Category: Contact NumberShow more

ContraFect Announces BARDA Contract Award for Up to $86.8

6 hours ago Globenewswire.com Show details

ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook. March 11, 2021 16:05 ET Source: BARDA, under contract number 75A501212C00021.

Category: Contact NumberShow more

ContraFect Corporation (CFRX) Stock Price, Quote & News

8 hours ago Stockanalysis.com Show details

Analyst Forecast. According to 3 analysts, the average rating for ContraFect stock is "Strong Buy." The 12-month stock price forecast is 13.75, which is an increase of 254.38% from the latest price.

Category: Contact NumberShow more

Contact Us. Get In Touch With The Contrado Team

2 hours ago Contrado.com Show details

00-13.30Monday to Friday EST 7.00-13.30 and Saturday 7.00-08.30. For PST 7.00-10.30 and Sat closed. Use live chat help by clicking chat button on our pages. For fast email response, use the form below. If you already have an order, please provide your order ID.

Category: Contact SupportShow more

ContraFect Announces BARDA Contract Award for Up to $86.8

7 hours ago Finance.yahoo.com Show details

(866) 691-5817Conference Call and Webcast Information. ContraFect will host a live conference call and webcast at 8:30 a.m. ET on March 12, 2021. To access the live conference call, please dial (866) 691-5817

Category: Contact NumberShow more

Are Institutions Heavily Invested In ContraFect

4 hours ago Nasdaq.com Show details

021-04-12

1. Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. ContraFect already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see ContraFect's historic earnings and revenue below, but keep in mind there's always more to the story. We note that hedge funds don't have a meaningful investment in ContraFect. Federated Hermes, Inc. is currently the largest shareholder, with 13% of shares outstanding. In comparison, the second and third...

Category: Contact NumberShow more

ContraFect Announces BARDA Contract Award for Up to $86.8

3 hours ago Apnews.com Show details

(866) 691-5817ContraFect will host a live conference call and webcast at 8:30 a.m. ET on March 12, 2021. To access the live conference call, please dial (866) 691-5817 and refer to conference ID 4278833. A webcast of the call will also be available under “Events” in the Investors & Media section of the ContraFect website at www.contrafect.com. The

Category: Contact NumberShow more

CFRX ContraFect Corp. Company Profile & Executives WSJ

8 hours ago Wsj.com Show details

Company profile for ContraFect Corp. including key executives, insider trading, ownership, revenue and average growth rates. View detailed CFRX description & address.

Category: Contact NumberShow more

About — CONTRACE

Just Now Contrace.org Show details

Leading experts on the COVID-19 contact tracing ecosystem. CONTRACE is a social enterprise based in Washington, DC, founded to help address the absence of a federal strategy to scale the contact tracing workforce for COVID-19. Launched in April, 2020, CONTRACE was the first organization to nationally recruit individuals to work or volunteer as

Category: Contact NumberShow more

ContraFect Corporation to Present at the 2021 Cantor

1 hours ago Nz.finance.yahoo.com Show details

Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.. Activities related to exebacase during the period of performance under the contract will be funded in part with federal funds from HHS; ASPR; BARDA, under contract number 75A501212C00021.

1. Author: Contrafect Corporation

Category: Contact NumberShow more

CFRX 13F Hedge Fund and Asset Management Owners

4 hours ago Whalewisdom.com Show details

28 WELLS AVENUE YONKERS, NY 10701. ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to

Category: Contact NumberShow more

CFRX Stock Forecast, Price & News (ContraFect) MarketBeat

6 hours ago Marketbeat.com Show details

The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

Category: Contact NumberShow more

CFRX – Novel Treatment via Lysins, Breakthrough FDA Status

3 hours ago Frugalnorwegian.com Show details

36:00 – The Contrafect Phase 2 study ‘was a robust study. These are data you should be able to bank on b/c the quality of the study.’ 40:15 – ‘We need new treatment’ for Staph bacteremia; Cara Cassino M.D. (ContraFect CMO) 42:50 – study was a novel Phase2 superiority designed trial – very rare as unicorns

Category: Contact NumberShow more

Contrafect (CFRX) Stock Analysis: Price, Forecast, and News

6 hours ago Investorsobserver.com Show details

Contrafect (CFRX) Company Description ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections.

Category: Contact NumberShow more

ContraFect Reports First Quarter 2021 Financial Results

6 hours ago Ca.finance.yahoo.com Show details

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong financial position with cash and investments of $87.2 million as of March 31, 2021 YONKERS, New York, May 14, 2021 (GLOBE NEWSWIRE) -- ContraFect

Category: Contact NumberShow more

What Are Analyst Opinions Regarding ContraFect Corporation

Just Now Baxterreport.com Show details

The total number of common shares currently owned by the public is 39.33 million. CFRX does have institutional investors; and they hold 63.90% of the stock. ContraFect Corporation – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

CFRX Ownership Information for CONTRAFECT CORPORATION

3 hours ago Msn.com Show details

91.24%. Mutual Fund Ownership Institutional Ownership. Mutual Fund Name. Shares Held (% Change) % Outstanding. Vanguard US Total Market Shares Index ETF AUD. 811,988 (0.38) 2.92. iShares Russell

Category: Contact NumberShow more

ContraFect : New Phase 2 Exebacase Data Presented at

7 hours ago Marketscreener.com Show details

YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, …

Category: Contact NumberShow more

ContraFect Announces BARDA Contract Award for Up to $86.8

Just Now Ca.finance.yahoo.com Show details

BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim futility analysis anticipated in H2 2021 Phase 3 DISRUPT study has the potential to serve as the basis for U.S. FDA product approval Conference call to be held on March 12, 2021 at 8:30

Category: Contact NumberShow more

SEC FORM D

4 hours ago Sec.gov Show details

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996

Category: Contact NumberShow more

A PlaceboControlled, DoseEscalating Study to Examine the

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02439359

Category: Contact NumberShow more

Glancy Prongay & Murray LLP Announces Business Wire

3 hours ago Businesswire.com Show details

310-201-9150Contacts. Glancy Prongay & Murray LLP Lesley Portnoy, 310-201-9150 or 888-773-9224 Bryan Faubus, 212-682-5340 [email protected] www.glancylaw.com

Category: Contact NumberShow more

EX10.1

4 hours ago Sec.gov Show details

ContraFect Share : Total (BARDA share plus ContraFect share) 0001 : 15 March 2021 through 14 February 2022 : Conduct a Phase 3 clinical trial, supportive manufacturing, futility analysis (60%) will be conducted and reviewed by the DSMB $ 9,767,226 $ 31,056,909 $ 40,824,135

Category: Contact NumberShow more

Board of Directors Investor Relations Vericel Corporation

9 hours ago Vcel.com Show details

Gilman served as the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation until his retirement in April 2019. He previously served as Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals from September 2010 until its acquisition by Merck & Co., in January 2015.

Category: Contact NumberShow more

CFRX: R&D Symposium Highlights Positive Data for Exebacase

2 hours ago Wfn1.com Show details

ContraFect was recently awarded a $6.9 million grant from CARB-X to support the development of amurin drug candidates. View Exhibit V. Financial Update On May 10, 2019, ContraFect announced financial results for the first quarter of 2019. As expected, the company did not report any revenues for the quarter.

Category: Contact NumberShow more

Contact Us Get In Touch With The Contrado Team

1 hours ago Contrado.ca Show details

Questions? Don't hesitate to contact Contrado with your question. We are super helpful and highly experienced suppliers of printed products.

Category: Contact SupportShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is ContraFect Corp.?

Visit a quote page and your recently viewed tickers will be displayed here. ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections.

Where is the mailing address for ContraFect biotechnology?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at (914) 207-2300 or via email at [email protected]

Are there any analysts that think ContraFect is a buy?

There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ContraFect stock. View analyst ratings for ContraFect or view top-rated stocks. What stocks does MarketBeat like better than ContraFect?

When did ContraFect co report its earnings results?

ContraFect Co. (NASDAQ:CFRX) posted its earnings results on Monday, May, 17th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. View ContraFect's earnings history.

Popular Brands

Costco
Cisco
Ccu
Cae